Meet us next:   BIO International Convention 2025 – 4 September  ●  ELRIG – Drug Discovery in Scotland 2025 – 17 September  ●  The Cell & Gene Meeting on the Mesa 2025 – 6-8 October (in person) & 9-10 October (virtual)  ●  ELRIG – Drug Discovery – 21-22 October  ●  more on our events calendar
Prices for NutriStem, NutriCoat, and NutriFreez products will increase effective 1st August. Lock in the current price by getting your order by 31st July.

Recombinant human IL-6 protein

QK093

Brand: Qkine

Interleukin-6 (IL-6) is a multifunctional cytokine that regulates immune responses and inflammation. It is produced by various cells, including immune cells such as T cells and macrophages, as well as non-immune cells like fibroblasts and endothelial cells. 

Human IL-6 has a molecular weight of 20.9 kDa. This protein is animal origin-free, carrier-free and tag-free to ensure its purity with exceptional lot-to-lot consistency. IL-6 is suitable for the culture of reproducible and high-quality hematopoietic stem cells and other relevant cells. 

Currency: 

Product name Catalog number Pack size Price Price (USD) Price (GBP) Price (EUR)
Recombinant human IL-6 protein, 25 µg QK093-0025 25 µg (select above) $ 280.00 £ 205.00 € 240.00
Recombinant human IL-6 protein, 50 µg QK093-0050 50 µg (select above) $ 410.00 £ 305.00 € 357.00
Recombinant human IL-6 protein, 100 µg QK093-0100 100 µg (select above) $ 620.00 £ 455.00 € 532.00
Recombinant human IL-6 protein, 500 µg QK093-0500 500 µg (select above) $ 2,500.00 £ 1,840.00 € 2,150.00
Recombinant human IL-6 protein, 1000 µg QK093-1000 1000 µg (select above) $ 3,950.00 £ 2,900.00 € 3,388.00

Note: prices shown do not include shipping and handling charges.

Qkine company name and logo are the property of Qkine Ltd. UK.

Alternative protein names

B-cell stimulatory factor 2 (BSF-2)
CTL differentiation factor (CDF)
Hybridoma growth factor
Interferon beta-2 (IFN-beta-2)

Species reactivity

human

species similarity:
mouse – 39%
rat – 38%
porcine – 59%
bovine – 55%

Frequently used together:

Summary

  • High purity human IL-6 protein (Uniprot number: P05231)
  • 20.9 kDa (monomer)
  • >98%, by SDS-PAGE quantitative densitometry
  • Expressed in E. coli
  • Animal origin-free (AOF) and carrier protein-free
  • Manufactured in Qkine's Cambridge, UK laboratories
  • Lyophilized from HEPES, NaCl
  • Resuspend in sterile-filtered water at >50 µg/ml, add carrier protein if desired, prepare single use aliquots and store frozen at -20 °C (short-term) or -80 °C (long-term).
Handling and Storage FAQ

Featured applications

  • Stimulation of activated B cell proliferation
  • Stimulation of T cell differentiation
  • Hematopoietic stem cell regulation
  • Proliferation and differentiation of erythrocytes, leukocytes and platelets 

Bioactivity

IL-6 protein activity is determined using the IL-6-responsive firefly luciferase reporter assay. Transfected HEK293T cells are treated in triplicate with a serial dilution of IL-6 for 24 hours. Firefly luciferase activity is measured and normalised to the control Renilla luciferase activity. Data from Qk093 lot #204594. EC50 = 1.46 ng/mL (70 pM) 

Qk093-IL-6-Datasheet-graph_-Data

Purity

Recombinant IL-6 migrates as a major band at approximately 20 kDa in non-reducing (NR) and at approximately 18 kDa in reduced (R) conditions. No contaminating protein bands are present. The purified recombinant protein (3 µg) was resolved using 15% w/v SDS-PAGE in reduced (+β-mercaptoethanol, R) and non-reduced (NR) conditions and stained with Coomassie Brilliant Blue R250. Data from Qk093 lot #204599. 

IL-6-Gel-1024x1024

Further quality assays

  • Mass spectrometry, single species with the expected mass
  • Endotoxin: <0.005 EU/μg protein (below the level of detection)
  • Recovery from stock vial: >95%

Qk093-IL-6-Datasheet-graph_-Comparison

Qkine IL-6 is more biologically active than a comparable alternative supplier protein. Quantitative luciferase assay with Qkine IL-6 (Qk093, green) and alternative supplier IL-6 (Supplier B, black). Cells were treated in triplicate with a serial dilution of IL-6 for 24 hours. Firefly luciferase activity was measured and normalized to control Renilla luciferase activity. Qk093 EC50 1.85 ng/ml, Supplier B EC50 5.74 ng/ml.

Protein background

Interleukin-6 (IL-6) is a multifunctional cytokine that plays a crucial role in regulating the immune response, inflammation, and various physiological processes. IL-6 is produced by a variety of cells, including T cells, B cells, monocytes, fibroblasts, endothelial cells, and adipocytes [1].

IL6 protein is a pleiotropic cytokine that belongs to the interleukin family of proteins. IL-6 adopts a four-helix bundle structure, with helices A and D forming the receptor-binding site [2]. It is glycosylated, influencing stability and activity. IL-6 binds to IL-6 receptor (IL-6R), forming a hexameric complex with gp130, initiating downstream signaling via the JAK/STAT pathway. Conformational changes upon receptor binding facilitate signaling.

IL-6 has a primary involvement in the acute phase response, the immediate reaction to infection, injury, or inflammation. IL-6 stimulates the production of acute-phase proteins such as C-reactive protein (CRP), fibrinogen, and serum amyloid A, which help to enhance the immune response and facilitate tissue repair [3,4].

IL6 protein plays a key role in the regulation of the immune system. It promotes the differentiation of B cells into antibody-producing plasma cells and stimulates the proliferation and activation of T cells, enhancing the adaptive immune response. IL-6 acts on various immune cells to modulate inflammation, promoting the recruitment of immune cells to sites of infection or injury [5,6]. IL-6 has diverse effects on different tissues and organs throughout the body. It has been implicated in the regulation of metabolism, with studies suggesting that IL-6 may play a role in energy balance, glucose metabolism, and lipid metabolism. IL-6 has been shown to have both pro- and anti-inflammatory effects depending on the context and the cells involved [7].

Dysregulated IL-6 signaling has been associated with various pathological conditions, including autoimmune diseases, chronic inflammation, and cancer. Elevated levels of IL-6 have been observed in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease, where it contributes to tissue damage and disease progression [8].

Background references

  1. Rose-John, S., & Heinrich, P. C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 436, 241–259 (2012).
  2. Kishimoto, T. Interleukin-6: Discovery of a pleiotropic cytokine. Arthritis Res. Ther. 12(Suppl 1), S2 (2010).
  3. Tanaka, T., Narazaki, M. & Kishimoto, T. Interleukin-6: From bench to bedside. Nat. Rev. Immunol. 20, 230–244 (2020).
  4. Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta – Mol. Cell Res. 1813, 878–888 (2011).
  5. Hunter, C. A., & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448–457 (2015).
  6. Rincon, M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 33, 571–577 (2012).
  7. Tanaka, T. & Kishimoto, T. The biology and medical implications of interleukin-6. Cancer Immunol. Res. 2, 288–294 (2014)
  8. Jones, S. A. & Jenkins, B. J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18, 773–789 (2018).